Souhaitez-vous accéder aux communiqués récents ?

Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Oncology Based In-Vivo CRO Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global market for...

SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...

CARGO Therapeutics Announce Pricing of IPO

Announced complete response in first patient with lymphoma treated with MT-601 in Phase 1 APOLLO trial following CAR T relapse Received Orphan Drug Designation (ODD) from European Medicines Agency...

Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated...

Dublin, Sept. 25, 2023 (GLOBE NEWSWIRE) -- The "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma),...

Vancouver, Sept. 14, 2023 (GLOBE NEWSWIRE) -- The global Minimal Residual Disease (MRD) market size was USD 1,095.3 Million in 2021 and is expected to register a revenue CAGR of 16.04% during the...

LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in...

LOTIS-5: Updated safety run-in results from Phase 3 trial demonstrate 80% ORR, 50% CR rate and median DoR of 8 months with no new safety signals LOTIS-7: Study design of trial evaluating ZYNLONTA® in...

Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive...